SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a launch failure where Blue Origins rocket placed the BlueBird 7 satellite into an unusable, off-nominal orbit, prompting investors to debate the company's reliance on launch partners versus its long-term commercial potential. While some in the community see the sharp sell-off as a strategic buying opportunity due to insurance coverage and intact fundamentals, others are expressing frustration over management's communication and the potential impact on future launch cadence.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility as investors clash over whether the recent price surge represents a legitimate breakout tied to global event expansion or a classic pump-and-dump scheme. The community is deeply divided, with some traders highlighting successful price action while others aggressively warn of manipulation, potential rug-pull risks, and the dangers of chasing hype in the memecoin space.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing massive volatility and high trading volume as investors chase speculative gains fueled by an executive order to fast-track psychedelic research. The community is sharply divided, with bulls betting on a short squeeze due to a limited float and potential government support, while bears warn of pump-and-dump mechanics, potential dilution, and a lack of direct clinical data connecting the stock to the reported ibogaine catalyst.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following reports that it is in talks with Google to develop custom AI chips, including a memory processing unit and an inference-optimized TPU. The community is actively discussing how this potential partnership, aimed at optimizing AI efficiency, positions Marvell as a key infrastructure player in a market shifting its focus from training to inference workloads.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors rally around the company's confirmed acquisition of a majority stake in the Tanbreez rare earth project, a key milestone that materially de-risks the asset and fuels speculation regarding future government investment and supply chain significance. The community is actively discussing the stock's potential for a massive short squeeze, with many pointing to heavy volume and limited borrow availability as signals that the stock is poised for significant upside.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is currently a focal point for investors debating its transition from a pure-play Bitcoin miner to an AI infrastructure and power capacity operator. The community is actively tracking potential short squeeze dynamics, contrasting the stock's recent volatility and management criticism against bullish sentiment surrounding institutional accumulation and long-term infrastructure value.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is experiencing intense volatility as retail traders push the stock through significant intraday swings, drawing heavy attention to its low-float status and high short interest. While bulls are banking on a potential short squeeze and upcoming earnings catalysts, the community remains deeply divided, with many debating whether the rapid price movements signal real growth or are merely a classic pump-and-dump cycle.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as frustrated investors discuss the relentless rally in semiconductor stocks, which has driven this leveraged bear ETF to new lows. The community is actively debating whether the current market environment is a parabolic blow-off top driven by AI exuberance and geopolitical distractions, or if they should continue averaging down in anticipation of a sharp sector pullback.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is capturing significant market attention following a major executive order that prioritizes and fast-tracks the federal review and research of psychedelic-based treatments for mental health conditions. Investors and the community are actively debating the company's competitive advantage as a leader in Phase 3 psilocybin trials, with many closely monitoring potential regulatory tailwinds and the upcoming clinical data readouts.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining intense investor attention as participants speculate on imminent data readouts from the REGAL Phase 3 trial and upcoming AACR conference presentations for SLS009. The community is deeply divided, with bulls pointing to extended survival signals and institutional positioning as catalysts for a potential squeeze, while bears highlight concerns over trial design and the company's long-term financial viability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given a consensus rating of "Buy" by the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One...

Wall Street Zen Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Hold"

Wall Street Zen upgraded shares of Spyre Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $95.00 at JonesTrading

JonesTrading increased their target price on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the company a "buy" rating in a research report on Friday...

Top Biotech Stocks To Watch Today - April 16th

Danaher, Vertex Pharmaceuticals, argenex, Moderna, United Therapeutics, Capstone Therapeutics, and Spyre Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop, manufacture, or comm...

Spyre Therapeutics (NASDAQ:SYRE) Sees Large Volume Increase on Analyst Upgrade

Spyre Therapeutics (NASDAQ:SYRE) Sees Strong Trading Volume After Analyst Upgrade...

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up After Analyst Upgrade

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade...

Robert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

Robert W. Baird increased their price objective on shares of Spyre Therapeutics from $65.00 to $90.00 and gave the company an "outperform" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>Spyre is looking forward to developing the drug as a single treatment, as well as in combination with its investigational antibodies SPY002 or SPY003.</li><li>TD Cowen says Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001.</li><li>Leerink continues to view the trial data as a best-case outcome for SPY00, one which derisks both its potential as a monotherapy and backbone in future combination regimens.</li></ul>Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data, with several noting the company’s experimental drug’s potential against Takeda’s Entyvio.The stock marked its highest single-day gain on Monday since June 2023.Earlier in the day, Spyre announced positive data from part A of its phase 2 trial of SPY001 in the treatment of moderate-to-severely active ulcerative colitis. The company said that the trial met its primary endpoint of statistically significant reduction in disease activity.The drug was further well tolerated though six subjects experienced treatment-emergent adverse events, including a serious event which the company deems as not related to the drug.Spyre is looking forward to developing the drug as a single treatment as well as in combination with its investigational antibodies SPY002 or SPY003.<h2 class="st-heading-2">Analyst Take Away</h2>TD Cowen said Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001. The firm has a ‘Buy’ rating on Spyre.Wedbush analyst David Nierengarten, meanwhile, raised the firm's price target on Spyre to $80 from $65 and kept an ‘Outperform’ rating on the shares. Spyre's SPY001 monotherapy surpassed historical benchmarks for Takeda's (TAK) Entyvio with 40% clinical remission and 51% endoscopic improvement, yielding an anticipated upside scenario, the analyst told investors in a research note.Leerink, which also has an ‘Outperform’ rating on the stock, raised the firm's price target on Spyre Therapeutics to $106 from $49. Leerink continues to view the trial data as a best-case outcome for SPY001, one which derisks both its potential as a monotherapy and backbone in future combination regimens. The target change reflects the firm's increased conviction and higher probability of success for SPY001 opportunities in UC and Crohn's disease, it said.Overall, the firm believes these "striking initial” study results represent best case data for SPY001, suggesting positively differentiated efficacy vs. Entyvio across a broad range of objective and symptomatic measures. The data position SPY001 as a leading agent in this multi-billion-dollar class, argues Leerink.Stoked by the data, BTIG analyst Julian Harrison also raised the firm's price target on Spyre to $98 from $70, and kept a ‘Buy’ rating on the shares while raising the firm's view of the odds of success for SPY001 combos in UC to 80% following the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SYRE stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SYRE">SYRE stock</a> has gained nearly 400% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/eras-stock-slumps-against-rvmd-rally-analyst-stays-bullish/cZJ8IHGRIuH">ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data

Equity

Earlier in the day, Spyre said that part of its phase 2 ulcerative colitis trial met its primary endpoint of statistically significant reduction in disease activity.


Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $106.00

Leerink Partners raised their price objective on Spyre Therapeutics from $49.00 to $106.00 and gave the company an "outperform" rating in a research note on Monday...

Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug

Spyre Therapeutics stock jumps after Phase 2 SKYLINE data; SPY001 shows efficacy in ulcerative colitis as analysts maintain bullish outlook.read more...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

SYRE
Spyre Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SYRE News

SYRESpyre Therapeutics Inc